La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Evaxion Biotech Bilan de santé
Santé financière contrôle des critères 3/6
Evaxion Biotech has a total shareholder equity of $1.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.2M and $21.1M respectively.
Informations clés
0%
Ratio d'endettement
US$0
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | US$11.73m |
Fonds propres | US$1.25m |
Total du passif | US$21.06m |
Total des actifs | US$15.23m |
Mises à jour récentes de la santé financière
Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Analyse de la situation financière
Passif à court terme: EVAX's short term assets ($11.7M) exceed its short term liabilities ($7.1M).
Passif à long terme: EVAX's short term assets ($11.7M) do not cover its long term liabilities ($14.0M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: EVAX is debt free.
Réduire la dette: EVAX has no debt compared to 5 years ago when its debt to equity ratio was 97.8%.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: EVAX has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: EVAX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.3% each year